VistaGen Therapeutics is a clinical-stage biopharmaceutical company concentrating on developing new generation medicines for depression and other central nervous system (CNS) disorders. The lead CNS product candidate, AV-101, is a new generation antidepressant drug candidate in Phase 2 development. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat major depressive disorder (MDD), with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. In addition to the AV-101 programs, VistaStem, VistaGen’s wholly owned subsidiary, is focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. VistaGen is utilizing its CardioSafe 3D to participate in the FDA's Comprehensive in-vitro Proarrhythmia Assay (CiPA) initiative designed to change the landscape of nonclinical drug development by providing a more complete and accurate assessment of potential drug effects on cardiac risk using stem cell-derived heart cells and in vitro ion channel data. In this podcast, Dr. Snodgrass discusses VistaStem’s stem cell technology applications as well and their CardioSafe 3D™ program. Make sure to subscribe, review and stay tuned to Future Tech Podcast for more on Future Tech news. Contribute Bitcoin to fuel our interviews and keep us going!